Big Pharma Update: What Big Pharma is Looking for In Partnering Opportunities
Thus far, 2009 has marked unprecedented changes and challenges within the biotechnology industry. Big pharma has responded to these challenges through mega mergers, high-profile consolidations, and high-value licensing deals. Couple this with Congress' impending health care reform measures and pressure to lower drug prices along with changes at the FDA, it is no wonder big pharma is taking dramatic steps to protect and enhance their opportunities for long-term growth. Small to medium-sized life sciences companies have also been forced to make changes as they struggle to retain value, maximize market potential and reduce risks.
In this session, panelists will explore: